JP2017507151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507151A5 JP2017507151A5 JP2016555458A JP2016555458A JP2017507151A5 JP 2017507151 A5 JP2017507151 A5 JP 2017507151A5 JP 2016555458 A JP2016555458 A JP 2016555458A JP 2016555458 A JP2016555458 A JP 2016555458A JP 2017507151 A5 JP2017507151 A5 JP 2017507151A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- cancer
- eribulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461947398P | 2014-03-03 | 2014-03-03 | |
| US61/947,398 | 2014-03-03 | ||
| PCT/US2015/018335 WO2015134399A1 (en) | 2014-03-03 | 2015-03-02 | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017507151A JP2017507151A (ja) | 2017-03-16 |
| JP2017507151A5 true JP2017507151A5 (enExample) | 2018-08-30 |
Family
ID=54055761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555458A Pending JP2017507151A (ja) | 2014-03-03 | 2015-03-02 | がんの治療のための併用療法としてのエリブリン及びｍＴＯＲ阻害剤の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20170071903A1 (enExample) |
| EP (1) | EP3113775A4 (enExample) |
| JP (1) | JP2017507151A (enExample) |
| KR (1) | KR20160135230A (enExample) |
| CN (1) | CN106029070A (enExample) |
| AU (1) | AU2015225436A1 (enExample) |
| CA (1) | CA2940983A1 (enExample) |
| IL (1) | IL247586A0 (enExample) |
| RU (1) | RU2016136504A (enExample) |
| SG (1) | SG11201607298QA (enExample) |
| WO (1) | WO2015134399A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2522663T3 (pl) | 2004-06-03 | 2015-08-31 | Eisai R&D Man Co Ltd | Produkty pośrednie do otrzymywania halichondryny B |
| KR101495951B1 (ko) | 2009-03-30 | 2015-02-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 리포솜 조성물 |
| KR102265952B1 (ko) | 2013-06-26 | 2021-06-16 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도 |
| EP3449921B1 (en) * | 2016-04-28 | 2023-05-31 | Eisai R&D Management Co., Ltd. | Eribulin for inhibiting tumor growth |
| US11419856B2 (en) | 2017-11-20 | 2022-08-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| WO2020097625A1 (en) * | 2018-11-09 | 2020-05-14 | G1 Therapeutics, Inc. | Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101415409B (zh) * | 2006-04-05 | 2012-12-05 | 诺瓦提斯公司 | 用于治疗癌症的治疗剂的组合 |
| JP6141016B2 (ja) * | 2009-08-27 | 2017-06-07 | バイオノミックス リミテッド | 増殖性疾患の治療のための併用療法 |
| JP2014508165A (ja) * | 2011-03-02 | 2014-04-03 | モルフォテック、インク． | 乳癌の治療のためのエリブリンおよびファーレツズマブの共投与 |
| JP2015514113A (ja) * | 2012-04-02 | 2015-05-18 | メリマック ファーマシューティカルズ インコーポレーティッド | 単一特異性および二重特異性抗ｉｇｆ−１ｒおよび抗ｅｒｂｂ３抗体の用法および用量 |
-
2015
- 2015-03-02 SG SG11201607298QA patent/SG11201607298QA/en unknown
- 2015-03-02 EP EP15758504.3A patent/EP3113775A4/en not_active Withdrawn
- 2015-03-02 CN CN201580011593.4A patent/CN106029070A/zh active Pending
- 2015-03-02 KR KR1020167027369A patent/KR20160135230A/ko not_active Withdrawn
- 2015-03-02 JP JP2016555458A patent/JP2017507151A/ja active Pending
- 2015-03-02 WO PCT/US2015/018335 patent/WO2015134399A1/en not_active Ceased
- 2015-03-02 RU RU2016136504A patent/RU2016136504A/ru unknown
- 2015-03-02 AU AU2015225436A patent/AU2015225436A1/en not_active Abandoned
- 2015-03-02 CA CA2940983A patent/CA2940983A1/en not_active Abandoned
- 2015-03-02 US US15/123,476 patent/US20170071903A1/en not_active Abandoned
-
2016
- 2016-08-31 IL IL247586A patent/IL247586A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507151A5 (enExample) | ||
| RU2016136504A (ru) | ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ | |
| US20160287605A1 (en) | Combination therapy | |
| JP2016528162A5 (enExample) | ||
| JP2009539769A5 (enExample) | ||
| JP7530116B2 (ja) | エムトール信号伝達抑制剤を有効成分として含む癌の予防又は治療用薬剤学的組成物 | |
| MX2010010621A (es) | Metodo y composiciones para el tratamiento del cancer. | |
| CN107666906A (zh) | 用于治疗癌症的方法 | |
| Ding et al. | SAHA triggered MET activation contributes to SAHA tolerance in solid cancer cells | |
| JP2019501185A (ja) | 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット | |
| WO2018213424A1 (en) | Methods for treating cancer | |
| CN102834094B (zh) | 有机化合物的组合产品及其制药用途 | |
| JP2021505669A5 (enExample) | ||
| CN107708700A (zh) | 用于治疗癌症的方法 | |
| EP3654967A1 (en) | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer | |
| JP7468829B2 (ja) | 癌を処置するための、癌治療剤と組み合わせたＩＲＥ１α阻害剤 | |
| CN101167741B (zh) | 莱菔硫烷和铂类药的抗癌联合制剂 | |
| RU2657604C2 (ru) | Противоопухолевый агент, включающий гидрат гидрохлорида иринотекана | |
| CA2868024A1 (en) | Methods of treating cancer using aurora kinase inhibitors | |
| EP3405199A1 (en) | Biomarkers for treating cancer with apilimod | |
| CN104640538B (zh) | 包含ndga 衍生物和索拉非尼的组合物以及其在治疗癌症中的用途 | |
| US10159659B2 (en) | Predicting response to cancer therapy | |
| CN109010333A (zh) | 脱氢弯孢霉素在抑制Hedgehog通路中的应用 | |
| CN104606189B (zh) | 一种化合物在制备mTOR抑制剂中的应用 | |
| CA3135916A1 (en) | Combined use of a-nor-5a androstane compound drug and anticancer drug |